CDEX Inc. Announces First Shipments of the New ValiMed(TM) Model CCT System to International Customers

A Very Important Milestone in the CDEX International Development Plan Is Reached Today With the First International Shipments of the New ValiMedTM Model CCT System

TUCSON, AZ–(EMWNews – August 21, 2008) – Following recent announcements of the reference

testing of ValiMed™ Units at four flagship hospitals in Europe and the

Middle East, CDEX Inc. (OTCBB: CEXI) announces today the first shipments of

the new ValiMed™ Model CCT System to international customers.

The new ValiMed™ Medication Validation and Narcotics Return System

(Model CCT), introduced first to the international market, is a

lightweight, compact table top instrument that can be used in virtually any

clinical environment where high-risk IV medications are compounded before

being dispensed to the patient, or where narcotics are returned after being

used.

“From the inception of the CCT through its final design we have integrated

new and innovative specifications to address market needs on a global

basis,” said Tim Shriver, CDEX Inc., COO. “Our engineering team worked hard

in developing this revolutionary device that encompasses all the proven

features of the current ValiMed™ VM Model as well as adding new

reporting capabilities and software enhancements to further increase the

operating value of the system.”

“The vision has become a reality. We have received very positive feedback

from our validation sites and have incorporated input from our

international customers and partners in the final design of the CCT. The

new ValiMed™ Model CCT will be displayed at major Pharmacy Conferences

in France, Spain and Italy this fall and we are very excited about going

forward,” said Pascal Pouligny, VP and GM of the Medication Safety

Division. “The shipment of CCTs to international customers marks another

major milestone in our International Development Plans.”

ABOUT CDEX

CDEX is a technology development company, currently manufacturing and

globally distributing advanced chemical detection products, based on its

patented Enhanced Photoemission Spectroscopy technology. The company

provides unique solutions to the challenges of identifying substances in

difficult to monitor environments. CDEX technology is being adapted to

market needs for medication validation, hazardous chemicals detection, and

brand protection through analysis of counterfeit substances. CDEX is

currently organized to serve two critical markets — Medication Safety and

Security. The ValiMed System™ is providing life-saving validation of

high-risk medications as well as identifying narcotics diversion in

healthcare facilities and pharmacies around the world. The ID2 Meth

Scanner™ is a revolutionary new tool in the global battle against the

growing scourge of methamphetamine abuse and its toxic impact on the

general public. Corporate headquarters and R&D facilities are located in

Tucson, Arizona with international offices in Paris, France. For more

information, visit www.CDEXInc.com and www.valimed.com or contact Steve

Schmidt, VP Corporate Communications, ([email protected]) at (520)

745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal

securities laws, and generally can be identified by words such as

“expects,” “plans,” “may,” “anticipates,” “believes,” “should,” “intends,”

“estimates,” and other similar words. These statements pose risks and

uncertainties that cannot be predicted or quantified and, consequently,

actual results may differ materially from those expressed or implied. Such

risks and uncertainties include, without limitation, the effectiveness,

profitability and marketability of products, the Protection of intellectual

property and proprietary information, and other risks detailed from

time-to-time in filings with the Securities and Exchange Commission. There

is no obligation to publicly update any forward-looking statements.